InvestorsHub Logo
icon url

rosemountbomber

01/10/20 3:32 PM

#239902 RE: KCSVEN #239893

KC a very good evaluation
icon url

isaeed

01/12/20 4:18 AM

#240222 RE: KCSVEN #239893

Simple answer to 1: Safety net in case something didnt go well with the amendment to the sNDA which later resulted in the Adcom which they knew would occur due to the amendment. They had suffered the Anchor adcom debacle, so they diluted at 18 which gave them enough funding for another year in case there was a significant delay in approval.
icon url

couldbebetter

01/12/20 9:28 AM

#240237 RE: KCSVEN #239893

KC, I certainly hope BP acquires AMRN so that a partnership deal for
Europe is not agreed to. Why would BP want to pay AMRN a royalty
if they can simply own it all for themselves. BP would have at least
11 years from approval to optimize revenues from the approval date.
The sooner BP acquires AMRN the more time they will have to prepare
for an effective launch over there.

I cannot understand why JT decided to partner in Canada with a company
that has no sales force? Why not a BP with experience in launching
and selling branded drugs there? Maybe JT had a good reason, but so
far I do not see it.

Hopefully, JT has been in discussions with BP regarding a takeout,
and JT is building the company until "the right" offer is accepted.